| Boston Scientific Bars Media From Meeting Boston Scientific, coming off a $1 billion loss last year and a costly sales halt of key products because of internal paperwork problems, took the rare step Tuesday of barring reporters from its annual meeting. online.wsj.com |
FDA Faces Avandia Decision A panel of outside medical experts convenes Tuesday to debate whether the FDA should pull diabetes drug Avandia from the market. online.wsj.com |
Trius Therapeutics Set to Price IPO SA Editor Mohit Manghnani submits:Trius Therapeutics (TSRX), a biopharmaceutical company focused on the discovery of antibiotics for serious, life-threatening infections, is expected to price its IPO soon. Business Overview (from prospectus)Complete Story » seekingalpha.com |
China Health-Reform 'No Easy Job' China's health minister said an ambitious overhaul of the Chinese health-care system won't be solved by money alone. online.wsj.com |
Geron: Buyer Beware In recent days, shares of biopharma company Geron (GERN) have gone viral, up over 20% in a week. News of a clinical trial for an embryonic stem cell therapy aimed at spinal cord injuries has captured the imagination of investors. History should give them pause. I've followed Geron off and on since the company went public. Hoover's reports that the IPO took place on July 31, 1996 at a price of $8 a share. 2 million shares were offered, with a total of 9.7 million shares outstanding after the IPO was completed. The result: a company with an $80 million market value and a pocket full of cash.Complete Story » seekingalpha.com |